{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:46:11Z","timestamp":1774316771627,"version":"3.50.1"},"reference-count":78,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151342","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T06:16:26Z","timestamp":1683612986000},"page":"151342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase"],"prefix":"10.1016","volume":"42","author":[{"given":"Sheron","family":"Latcha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chintan V.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.semnephrol.2023.151342_bib0001","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0002","series-title":"Childhood Leukemias","first-page":"709","article-title":"Acute complications","author":"Howard","year":"2006"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151342_bib0003","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/BF03401822","article-title":"Involvement of macrophage migration inhibitory factor (MIF) in experimental uric acid nephropathy","volume":"6","author":"Kim","year":"2000","journal-title":"Mol Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0004","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats","volume":"67","author":"S\u00e1nchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0005","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1093\/ndt\/gfp330","article-title":"A novel role for uric acid in acute kidney injury associated with tumor lysis syndrome","volume":"24","author":"Shimada","year":"2009","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.semnephrol.2023.151342_bib0006","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/pbc.20192","article-title":"Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia","volume":"44","author":"Hijiya","year":"2005","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1681\/ASN.2022040425","article-title":"Crystals or his(stones): rethinking AKI in tumor lysis syndrome","volume":"33","author":"Basile","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"16","key":"10.1016\/j.semnephrol.2023.151342_bib0008","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review","volume":"26","author":"Coiffier","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0010","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03150312","article-title":"Onco-nephrology: tumor lysis syndrome","volume":"7","author":"Wilson","year":"2012","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0011","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0002-9343(93)90174-N","article-title":"Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma","volume":"94","author":"Hande","year":"1993","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3324\/haematol.11575","article-title":"Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model","volume":"93","author":"Montesinos","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0002-9343(75)90597-5","article-title":"American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival","volume":"58","author":"Arseneau","year":"1975","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/10428190903456959","article-title":"Prognostic significance of acute renal injury in acute tumor lysis syndrome","volume":"51","author":"Darmon","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151342_bib0015","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.13403","article-title":"British Committee for Standards in Haematology Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology","volume":"169","author":"Jones","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0016","first-page":"890","article-title":"Enzymatic uricolysis: a study of the effect of a fungal urate\u2013oxydase","volume":"17","author":"Brogard","year":"1972","journal-title":"Rev Eur Etudes Clin Biol."},{"key":"10.1016\/j.semnephrol.2023.151342_bib0017","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0378-1119(91)90622-I","article-title":"Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations","volume":"109","author":"Yeldandi","year":"1991","journal-title":"Gene."},{"key":"10.1016\/j.semnephrol.2023.151342_bib0018","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.leu.2400850","article-title":"Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies","volume":"11","author":"Pui","year":"1997","journal-title":"Leukemia."},{"issue":"suppl 4","key":"10.1016\/j.semnephrol.2023.151342_bib0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/bjc.1998.432","article-title":"Advances in the management of malignancy-associated hyperuricaemia","volume":"77","author":"Mahmoud","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0020","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J Clin Oncol."},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151342_bib0021","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151342_bib0022","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1200\/JCO.2003.04.115","volume":"21","author":"Coiffier","year":"2003","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.semnephrol.2023.151342_bib0023","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2009.26.8896","article-title":"Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone\u2013results of a multicenter phase III study","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0024","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1093\/annonc\/mdr490","article-title":"A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome","volume":"23","author":"Vadhan-Raj","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1592\/phco.26.6.806","article-title":"Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults","volume":"26","author":"McDonnell","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151342_bib0026","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1345\/aph.1P296","article-title":"Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients","volume":"44","author":"Vines","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0027","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1177\/1078155218791333","article-title":"Single 6-mg dose of rasburicase: the experience in a large academic medical center","volume":"25","author":"Nauffal","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"23","key":"10.1016\/j.semnephrol.2023.151342_bib0028","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1182\/blood.V126.23.4511.4511","article-title":"A comparison of single dose rasburicase 3 mg versus 6 mg for the management of tumor lysis syndrome","volume":"126","author":"Kraus SK","year":"2015","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jcpt.12479","article-title":"The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis","volume":"42","author":"Yu","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/phar.1198","article-title":"Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome","volume":"33","author":"McBride","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151342_bib0031","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/1078155216644975","article-title":"Single 4.5\u2009mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome","volume":"23","author":"Patel","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0032","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/bmt.2010.212","article-title":"Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies","volume":"46","author":"Trifilio","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0033","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1592\/phco.28.6.685","article-title":"Evaluation of a single fixed dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer","volume":"28","author":"Reeves","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0034","unstructured":"Centers for Medicare and Medicaid Services. ASP drug pricing files. 2022. https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2022-asp-drug-pricing-files"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0035","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1078155216687152","article-title":"Rational use of rasburicase for the treatment and management of tumor lysis syndrome","volume":"24","author":"Shaikh","year":"2018","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0036","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/1078155217752075","article-title":"The value of fixed rasburicase dosing versus weight-based dosing in the treatment and prevention of tumor lysis syndrome","volume":"25","author":"Boutin","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0037","article-title":"The efficacy and cost-impact of rasburicase 3\u2005mg versus 6\u2005mg for the management of tumor lysis syndrome: a multicenter analysis","author":"Marjoncu","year":"2022","journal-title":"J Oncol Pharm Pract"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0038","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/1744666X.1.4.549","article-title":"Overcoming the immunologic response to foreign enzymes in cancer therapy","volume":"1","author":"Chester","year":"2005","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0039","unstructured":"Rasburicase [Package Insert]. Sanofi-Aventis US LLC; 2009."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40264-014-0255-7","article-title":"Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project","volume":"38","author":"Allen","year":"2015","journal-title":"Drug Saf"},{"issue":"20","key":"10.1016\/j.semnephrol.2023.151342_bib0041","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-03-416032","article-title":"Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone","volume":"120","author":"Pamba","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0042","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ajh.20738","article-title":"Methemoglobin\u2013it's not just blue: a concise review","volume":"82","author":"Umbreit","year":"2007","journal-title":"Am J Hematol."},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0043","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bcmd.2008.12.005","article-title":"The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis","volume":"42","author":"Nkhoma","year":"2009","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ccr3.495","article-title":"Rasburicase-induced methemoglobinemia: case report, literature review, and proposed treatment algorithm","volume":"4","author":"Sherwood","year":"2016","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0045","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.23182","article-title":"Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase","volume":"88","author":"Sonbol","year":"2013","journal-title":"Am J Hematol."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0046","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000351048","article-title":"Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency","volume":"130","author":"Cheah","year":"2013","journal-title":"Acta Haematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0047","doi-asserted-by":"crossref","first-page":"A87","DOI":"10.1016\/j.chest.2019.08.178","article-title":"A case of rasburicase-induced methemoglobinemia due to glucose-6-phosphate dehydrogenase deficiency treated with hyperbaric oxygen therapy","volume":"156","author":"Richert M","year":"2019","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0048","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjh.12415","article-title":"Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en R\u00e9animation Respiratoire et Onco-H\u00e9matologique","volume":"162","author":"Darmon","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0049","article-title":"Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer","volume":"3","author":"Cheuk","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.ajkd.2013.02.378","article-title":"Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis","volume":"62","author":"Lopez-Olivo","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0051","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1681\/ASN.2021070997","article-title":"Tumor lysis syndrome and AKI: beyond crystal mechanisms","volume":"33","author":"Arnaud","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151342_bib0052","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.1999.17.5.1589","article-title":"High-dose leucovorin as sole therapy for methotrexate toxicity","volume":"17","author":"Flombaum","year":"1999","journal-title":"J Clin Oncol."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151342_bib0053","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0054","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2710.2008.00966.x","article-title":"Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data","volume":"33","author":"Fukuhara","year":"2008","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0055","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00280-002-0552-1","article-title":"High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL)","volume":"51","author":"Skarby","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"issue":"27","key":"10.1016\/j.semnephrol.2023.151342_bib0056","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0057","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1172\/JCI108308","article-title":"7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate","volume":"57","author":"Jacobs","year":"1976","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0058","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151342_bib0059","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0060","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J Oncol Pharm Pract."},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151342_bib0061","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ekir.2022.10.029","article-title":"High dose methotrexate-induced acute kidney injury: incidence, risk factors, and recovery","volume":"8","author":"Latcha","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0062","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0063","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt197823168","article-title":"Effect of pleural effusion on high-dose methotrexate kinetics","volume":"23","author":"Evans","year":"1978","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151342_bib0064","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.1987.5.12.2017","article-title":"High-dose methotrexate: a critical reappraisal","volume":"5","author":"Ackland","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0065","unstructured":"FDA. Prescribing information. 2020. Accessed January 10, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/020140s024lbl.pdf"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151342_bib0066","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM197709222971203","article-title":"Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity","volume":"297","author":"Stoller","year":"1977","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0067","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155217729744","article-title":"A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration","volume":"25","author":"Cerminara","year":"2019","journal-title":"J Oncol Pharm Pract."},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0068","first-page":"745","article-title":"Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration","volume":"61","author":"Von Hoff","year":"1977","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151342_bib0069","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/phar.2145","article-title":"Management of patients with acute methotrexate nephrotoxicity with high-dose leucovorin","volume":"38","author":"Flombaum","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151342_bib0070","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/sj.bjc.6602337","article-title":"Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure","volume":"92","author":"Buchen","year":"2005","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151342_bib0071","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151342_bib0072","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151342_bib0073","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1080\/1042819021000032953","article-title":"Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy","volume":"43","author":"Krause","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"25","key":"10.1016\/j.semnephrol.2023.151342_bib0074","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151342_bib0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12885-021-09164-x","article-title":"Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study","volume":"22","author":"Schaff","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0076","unstructured":"Date UT. Glucarpidase: drug information, 2023. Accessed April 27, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125327lbl.pdf"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151342_bib0077","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2215\/CJN.08030621","article-title":"Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP Workgroup","volume":"17","author":"Ghannoum","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2023.151342_bib0078","unstructured":"Methotrexate. 2023. Accessed January 16, 2023, 2023. https:\/\/go.drugbank.com\/drugs\/DB00563"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:41:32Z","timestamp":1759448492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000529"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151342","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rescue Therapies for AKI in Onconephrology: Rasburicase and Glucarpidase","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151342"}}